ApoGen increases 2016 Series A funding round to $11 million
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Medisafe raises $14.5M and adds London office to reflect growth in Europe
New European investor Octopus Ventures led the Series B round with participation from another new backer, M Ventures — the Amsterdam-based, strategic, corporate venture capital arm of Merck KGaA, in Darmstadt, Germany